Solaray Ashwagandha 470 mg Review

Non-standardised root extract with no declared withanolide percentage on label. Realistic active content: 4-9 mg withanolides per 470 mg capsule at typical 1-2% withanolide concentration for non-standardised preparations, with substantial lot-to-lot variance. Compared to KSM-66's contracted 5% (= 23.5 mg withanolides per 470 mg gram-weight equivalent), Solaray delivers an estimated 25-40% of the trial-extract active load. Loses heavily on the criterion with 30% weight — the entire testosterone-trial evidence base depends on verifiable per-cap actives, which Solaray doesn't provide.

Generic root extract from Solaray's established supply chain. No KSM-66 or Sensoril patent license, no Solaray-specific clinical trial on the testosterone endpoint, no direct anchoring to the published RCT evidence base. The 30+ year brand longevity provides indirect QC consistency signal (no major recalls, no major scandals), which substitutes partially for trial-grade evidence — buyers can trust Solaray's bottle won't contain contaminants or wildly wrong dose, even if they can't trust it matches Wankhede 2015 / Lopresti 2019 active loads.

Solaray runs in-house QC labs + GMP-certified manufacturing facility. The brand's 50-year operational continuity provides implicit batch-to-batch consistency that mass-market generic brands lack. Solaray publishes internal QC standards (heavy metals tested below USP limits, microbial assays performed) but does not publish per-batch COA lookup or per-lot withanolide verification. The transparency tier is solidly above mass-market generic (Nature's Bounty) and roughly comparable to Himalaya — internal QC documentation rather than public per-batch lookup.

470 mg per cap is in the 300-600 mg gram-weight trial window for KSM-66 dosing, but the active-mg math is what matters: estimated 4-9 mg withanolides per cap is below the 12 mg active dose in Lopresti 2019 stress (240 mg KSM-66) and well below the 30 mg active dose in Wankhede 2015 / Lopresti 2019 testosterone (600 mg KSM-66). At 1 cap/day Solaray undershoots most clinical-trial active doses; at 2 caps/day it approaches the stress-trial active load but costs $30/month effective. Gram-weight alignment is OK, active-mg alignment is below trial doses.

$15/month at 1 cap/day = $0.25/cap = ~$0.03-0.06 per mg active withanolide (4-9 mg actives/cap). Per-mg cost is competitive with Nature's Bounty and slightly above NOW Foods, but the active-mg estimate has wide uncertainty bands because the standardisation isn't disclosed. Fair price for the legacy-brand trust + offline availability premium; $1 above Nutricost KSM-66 ($14, real patent, 30 mg actives) makes the value proposition specifically about brand and distribution rather than per-mg cost.